We are live on !
Find out more
Commodore Capital Portfolio holdings
AUM
$1.68B
Turnover
31.71%
1-Year Est. Return
375.52%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$287M
AUM Growth
+$36M
(+14%)
Cap. Flow
+$39.2M
Cap. Flow % of AUM
Cap. Flow %
13.67%
Top 10 Holdings %
Top 10 Hldgs %
59.07%
Holding
34
New
3
Increased
15
Reduced
4
Closed
5
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celcuity
CELC
|
+$22.4M |
| 2 |
Cytokinetics
CYTK
|
+$16.5M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$14.6M |
| 4 |
MacroGenics
MGNX
|
+$10.2M |
| 5 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
+$3.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$13.6M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$8.55M |
| 3 |
Relmada Therapeutics
RLMD
|
+$5.69M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$5.29M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$4.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.08% |
| 2 | Financials | 0.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Aclaris Therapeutics
ACRS
$552M
| $29.3M | 10.21% |
1,668,987
+640,903
| +62% | +$14.6M |
2020 Q4
2 quarters
|
|
|
STSA
2
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $21.8M | 7.61% |
3,096,729
+665,024
| +27% | +$3.59M |
2021 Q1
1 quarter
|
|
|
3
Celcuity
CELC
$3.19B
| $20.9M | 7.28% |
+870,967
| New | +$22.4M |
2021 Q2
0 quarters
|
|
4
C4 Therapeutics
CCCC
$376M
| $18.2M | 6.34% |
481,094
| – | – |
2020 Q4
2 quarters
|
|
5
DELISTED
Cymabay Therapeutics
CBAY
| $15.4M | 5.36% |
3,529,465
+545,952
| +18% | +$2.42M |
2020 Q4
2 quarters
|
|
|
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $14.9M | 5.19% |
440,869
+72,421
| +20% | +$1.85M |
2020 Q4
2 quarters
|
|
|
7
Cytokinetics
CYTK
$8.51B
| $13.9M | 4.86% |
+704,317
| New | +$16.5M |
2021 Q2
0 quarters
|
|
8
Kura Oncology
KURA
$855M
| $13M | 4.51% |
621,493
+99,938
| +19% | +$2.48M |
2020 Q4
2 quarters
|
|
9
Cogent Biosciences
COGT
$5.42B
| $11.1M | 3.86% |
1,367,582
+98,387
| +8% | +$831K |
2020 Q4
2 quarters
|
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $11M | 3.84% |
1,748,241
+19,200
| +1% | +$124K |
2020 Q4
2 quarters
|
|
11
Celldex Therapeutics
CLDX
$2.3B
| $10.8M | 3.77% |
323,437
-46,514
| -13% | -$1.28M |
2020 Q4
2 quarters
|
|
|
12
MacroGenics
MGNX
$143M
| $10.6M | 3.69% |
393,850
+347,220
| +745% | +$10.2M |
2021 Q1
1 quarter
|
|
13
VistaGen Therapeutics
VTGN
$7.97M
| $10.5M | 3.66% |
111,044
-13,279
| -11% | -$984K |
2020 Q4
2 quarters
|
|
|
14
Protagonist Therapeutics
PTGX
$8.96B
| $9.45M | 3.29% |
210,600
-139,000
| -40% | -$4.59M |
2020 Q4
2 quarters
|
|
15
DELISTED
ESSA Pharma
EPIX
| $8.05M | 2.81% |
281,911
+105,090
| +59% | +$3.05M |
2021 Q1
1 quarter
|
|
16
DELISTED
Kronos Bio
KRON
| $7.16M | 2.49% |
298,839
| – | – |
2020 Q4
2 quarters
|
|
|
GNCA
17
DELISTED
Genocea Biosciences, Inc.
GNCA
| $6.86M | 2.39% |
2,929,447
+57,823
| +2% | +$139K |
2020 Q4
2 quarters
|
|
18
Mereo BioPharma
MREO
$45M
| $6.53M | 2.27% |
2,059,729
+10,972
| +0.5% | +$36.8K |
2020 Q4
2 quarters
|
|
19
Dyne Therapeutics
DYN
$2.92B
| $6.42M | 2.24% |
305,125
-124,987
| -29% | -$2.35M |
2021 Q1
1 quarter
|
|
20
Xenon Pharmaceuticals
XENE
$3.42B
| $6.08M | 2.12% |
326,336
+24,944
| +8% | +$460K |
2020 Q4
2 quarters
|
|
21
DELISTED
Mersana Therapeutics
MRSN
| $5.83M | 2.03% |
17,169
| – | – |
2020 Q4
2 quarters
|
|
22
DELISTED
KalVista Pharmaceuticals
KALV
| $5.43M | 1.89% |
226,671
+12,204
| +6% | +$319K |
2021 Q1
1 quarter
|
|
23
PMV Pharmaceuticals
PMVP
$67.9M
| $4.27M | 1.49% |
125,000
| – | – |
2020 Q4
2 quarters
|
|
24
Inventiva
IVA
$876M
| $3.58M | 1.25% |
262,658
| – | – |
2020 Q4
2 quarters
|
|
25
Seres Therapeutics
MCRB
$21M
| $3.47M | 1.21% |
7,273
+208
| +3% | +$87.8K |
2021 Q1
1 quarter
|
|
Similar funds
SH
TP
IAIM
Commodore Capital's Q2 2021 Portfolio in Review
As of Q2 2021, Commodore Capital held 34 positions worth $287M, up 14% from $251M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Commodore Capital deployed $39.2M of net new capital in Q2 2021, opening 3 new positions and adding to 15 existing holdings. Its largest new stake was Celcuity: 870,967 shares worth $20.9M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $4.59M trimmed.
- Commodore Capital's largest Q2 2021 buy was Celcuity: 870,967 shares worth $20.9M.
- Commodore Capital added most to Aclaris Therapeutics in Q2 2021, an estimated $14.6M increase.
- Commodore Capital's biggest Q2 2021 reduction was Protagonist Therapeutics, cutting an estimated $4.59M.
- Commodore Capital fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $13.6M.
- Commodore Capital's ten largest holdings make up 59% of its $287M portfolio in Q2 2021.
- Commodore Capital opened 3 new positions and closed 5 in Q2 2021.
- Commodore Capital's portfolio value rose 14% quarter-over-quarter to $287M.
Based on Commodore Capital's 13F filing for Q2 2021, filed 16 Aug 2021.